Evidence map›Paper›PMID 38627145›Full record

ArticleVaccine2024

The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex.

Jose L Martínez, Nicholas Lemus, Tsoi Ying Lai, Mitali Mishra, Irene González-Domínguez, Eduard Puente-Massaguer, Madhumathi Loganathan, Benjamin Francis, Marie I Samanovic, Florian Krammer and 4 more

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Jose L MartínezDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States. Electronic address: joseluis.martinezguevara@mssm.edu.
Nicholas LemusDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Tsoi Ying LaiDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Mitali MishraDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Irene González-DomínguezDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Eduard Puente-MassaguerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Madhumathi LoganathanDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Benjamin FrancisDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Marie I SamanovicDepartment of Medicine, NYU Grossman School of Medicine, New York, New York, United States; NYU Langone Vaccine Center, NYU Grossman School of Medicine, New York, New York, United States.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, United States; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Mark J MulliganDepartment of Medicine, NYU Grossman School of Medicine, New York, New York, United States; NYU Langone Vaccine Center, NYU Grossman School of Medicine, New York, New York, United States.
Viviana SimonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, United States; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Peter PaleseDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Weina SunDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States. Electronic address: weina.sun@mssm.edu.
Icahn School of Medicine at Mount Sinai · USNew York University · US

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) - DMID 21-0012UM1AI148574 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Angelica Cifuentes Kottkamp, Anoma Nellore · 2020 to 2026
$23.9M
Evaluation of the FcgR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infectionR01AI145870 · NIAID · ROCKEFELLER UNIVERSITY · PI Peter Palese, JEFFREY Victor RAVETCH · 2019 to 2026
$8.4M
NIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93021C00014NIAID NIH HHS R01 AI145870NIAID NIH HHS UM1 AI148574
6 · The paper itself

Abstract

The head domain of the hemagglutinin of influenza viruses plays a dominant role in the antibody response due to the presence of immunodominant antigenic sites that are the main targets of host neutralizing antibodies. For the H1 hemagglutinin, five major antigenic sites defined as Sa, Sb, Ca1, Ca2, and Cb have been described. Although previous studies have focused on defining the hierarchy of the antigenic sites of the hemagglutinin in different human cohorts, it is still unclear if the immunodominance profile of the antigenic sites might change with the antibody levels of individuals or if other demographic factors (such as exposure history, sex, or age) could also influence the importance of the antigenic sites. The major antigenic sites of influenza viruses hemagglutinins are responsible for eliciting most of the hemagglutination inhibition antibodies in the host. To determine the antibody prevalence towards each major antigenic site, we evaluated the hemagglutination inhibition against a panel of mutant H1 viruses, each one lacking one of the "classic" antigenic sites. Our results showed that the individuals from the Stop Flu NYU cohort had an immunodominant response towards the sites Sb and Ca2 of H1 hemagglutinin. A simple logistic regression analysis of the immunodominance profiles and the hemagglutination inhibition titers displayed by each donor revealed that individuals with high hemagglutination inhibition titers against the wild-type influenza virus exhibited higher probabilities of displaying an immunodominance profile dominated by Sb, followed by Ca2 (Sb > Ca2 profile), while individuals with low hemagglutination inhibition titers presented a higher chance of displaying an immunodominance profile in which Sb and Ca2 presented the same level of immunodominance (Sb = Ca2 profile). Finally, while age exhibited an influence on the immunodominance of the antigenic sites, biological sex was not related to displaying a specific immunodominance profile.

Indexed as

Antibodies, ViralHemagglutination Inhibition TestsHemagglutinin Glycoproteins, Influenza VirusImmunodominant EpitopesInfluenza, HumanAdolescentAdultAgedAge FactorsAntibodies, NeutralizingAntigens, ViralCohort StudiesFemaleHumansInfluenza A Virus, H1N1 SubtypeMaleAntibodies, NeutralizingAntibodies, ViralAntigens, ViralHemagglutinin Glycoproteins, Influenza VirusImmunodominant EpitopesAntibody prevalenceHead domainImmune hierarchyProtectionVaccination

Identifiers

PMID38627145
PMCPMC11145762
OpenAlexW4394823882

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.